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Glioblastoma multiforme (GBM) constitutes the most common and the most aggressive
type of human tumors affecting the central nervous system. Prognosis remains dark
due to the inefficiency of current treatments and the rapid relapse. Paralleling other
human tumors, GBM contains a fraction of tumor initiating cells with the capacity to self-
renew, initiate and maintain the tumor mass. These cells were found in close proximity
to brain vasculature, suggesting functional interactions between brain tumor-initiating
cells (BTICs) and endothelial cells within the so-called vascular niche. However, the
mechanisms by which these cells impact on the endothelium plasticity and function
remain unclear. Using culture of BTICs isolated from a cohort of 14 GBM patients,
we show that BTICs secretome promotes brain endothelial cell remodeling in a VEGF-
independent manner. Gene array analysis unmasked that BTICs-released factors drove
the expression of Ptch2 in endothelial cells. Interestingly, BTICs produce desert hedgehog
(DHH) ligand, enabling a paracrine DHH/Ptch2 signaling cascade that conveys elevated
permeability and angiogenesis. Finally, DHH silencing in BTICs dramatically reduced
tumor growth, as well as vascularization and intra-tumor permeability. Collectively, our
data unveil a role for DHH in exacerbated tumor angiogenesis and permeability, which
may ultimately favor glioblastoma growth, and thus place the DHH/Ptch2 nexus as a
molecular target for novel therapies.
Keywords: glioma, brain endothelial cells, hedgehog, permeability, tumor vasculature
INTRODUCTION
Glioblastoma multiforme (GBM) is one of the most malignant cancers in adults with less than 5%
of patients surviving more than 2 years and a median survival range between 15 and 18 months
(Stupp et al., 2009). While current therapies include surgical resection, followed by a combined
radio-chemotherapy regime (Stupp et al., 2009), relapse is almost inevitable and remains fatal. GBM
are highly vascularized tumors, with large zone of hypoxia and necrosis and are highly addicted
to pro-angiogenic signaling pathways, among which is the vascular endothelial growth factor A
(VEGF-A; Olsson et al., 2006; Jain et al., 2007). Vascularization index, blood flux, and vascular
permeability and edema are thus important parameters directly linked to tumor aggressiveness
(Jain et al., 2007; Sorensen et al., 2009). Echoing this, the humanized anti-VEGF antibodies
bevacizumab, as well as novel anti-angiogenic therapies were developed to prune and/or normalize
the tumor blood supply (Carmeliet and Jain, 2011). However, recent randomized large clinical
studies failed to demonstrate the effectiveness of such therapies in first line treatment in GBM
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(Chinot et al., 2014). In this context, identification of new
molecular targets controlling endothelial plasticity is at the
utmost importance, as it may open new routes for more efficient
therapeutic strategies in GBM treatment.
The identification of cancer cells with stem-like properties
has contributed to a better knowledge of molecular and cellular
processes involved in tumor formation and treatment resistance
(Singh et al., 2003, 2004; Bao et al., 2006). Indeed, GBM are
believed to originate from such brain tumor-initiating cells
(BTICs) with the unique ability to self-sustain and renew the
tumor (Singh et al., 2003, 2004; Bao et al., 2006). Such studies
have highlighted the importance of both cellular hierarchy and
intratumoral heterogeneity inGBM (Verhaak et al., 2010; Brennan
et al., 2013; Patel et al., 2014). Similarly to neural stem cells,
BTICs are nested in a vascular niche, which provides a specific and
confinedmicroenvironment that favors bidirectional transference
between endothelial cells from the vascular wall and cancer
initiating cells from the tumor mass. In keeping with this, BTICs
were characterized in the vicinity of brain endothelial cells,
allowing close interaction and exchange of survival and fate signals
(Calabrese et al., 2007; Galan-Moya et al., 2011). Several studies
had also documented the ability of BTICs to transdifferentiate and
integrate the tumor vasculature (Ricci-Vitiani et al., 2010; Wang
et al., 2010; Cheng et al., 2013). However, the precise mechanism
by which BTICs impact on endothelial plasticity remains poorly
understood.
Among the putative candidates, the hedgehog (HH) pathway
is known to regulate stem cell maintenance, differentiation
and proliferation in embryonic development. Notably, the HH
network coordinates the blood–brain barrier integrity in both
development and adulthood in mouse models (Alvarez et al.,
2011). In pathological conditions, HH aberrant activation was
linked to tumor invasion, migration, and progression (Smyth
et al., 1999; Evangelista et al., 2006; D’Amico et al., 2015;
Qualtrough et al., 2015; Xu et al., 2015). Moreover, HH signaling
was found implicated in acquired chemoresistance and cancer
stem cell fate and properties (Bar et al., 2007; Justilien et al., 2014;
Kong et al., 2014; Takebe et al., 2015).
In the present work, we investigated the effects of patient-
derived BTICs-secreted factors on long-term endothelial cell
behavior. We found that BTICs secretome conveys endothelial
remodeling in a VEGF/Src-independent manner. We discovered
that BTICs-secreted factors induce the expression of the HH
receptor Ptch2, in endothelial cells. Interestingly, BTICs produce
desert hedgehog (DHH) ligand, enabling a paracrine DHH/Ptch2
signaling cascade that culminates in vascular leakage and
increased angiogenic potential. Finally, DHH knockdown in
BTICs dramatically reduced tumor formation and growth, as well
as intra-tumor permeability. Thus, our data place DHH/Ptch2
nexus as a potential candidate for therapeutic intervention in
GBM.
MATERIALS AND METHODS
Cell Culture
Immortalized human cerebral microvascular endothelial
cells (hCMEC/D3) were maintained as described previously
in (Le Guelte et al., 2012). Immortalized human umbilical
vein endothelial cells (HUVEC, Ea.hy926 clone) and human
embryonic kidney HEK-293T cells were obtained from ATCC
(LGC Standards, Molsheim, France) and expanded in DMEM
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin (Life Technologies, Cergy-Pontoise,
France). Human bone marrow endothelial cells (hBMEC) were
obtained from (Lonza, Levallois, France) and maintained in
complete EBM-2 medium, as per manufacturer’s instructions
(Lonza).
Patient-derived glioblastoma-initiating cells (BTICs) were
isolated from primary glioblastoma tumor biopsies and cultured
as tumorspheres as previously described (Galan-Moya et al.,
2011; Treps et al., 2015). BTICs-derived conditioned media were
prepared from 1.106 cells cultured in DMEM/F12 additive-free
medium. Supernatants were collected 3 days later, filtered on a
0.45 mmmembrane and stored at 80°C.
Animals
This study was carried out in accordance with the
recommendations of local ethics committee (Paris Descartes
university, Paris, France) and approved by French Ministry of
Research (agreement number #00754.02). All experiments were
performed in compliance with the European Convention for
the Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes (ETS 123). Six weeks-old female BALB/c
nude mice were obtained from Janvier Labs (Saint-Berthevin,
France).
Reagents and Secondary Antibodies
Recombinant VEGF-A165 was purchased from R&D Systems
(Bio-Techne, Lille, France). VEGF-R2 inhibitor (SU5416) and
Src kinase inhibitor (SU6656) were from Tocris (Bio-Techne).
Hypoxyprobe Red549 Kit was obtained from Hypoxyprobe
(Burlington, MA, USA). Growth factor-free matrigel was from
BD Biosciences (Le Pont-de-Claix, France). FITC-coupled 40
kDa Dextran and Alexa488-coupled phalloidin were from Life
Technologies. HRP-conjugated and fluorochrome-conjugated
specie-specific secondary antibodies were purchased from
Jackson Immunoresearch (Suffolk, UK) and Life Technologies,
respectively.
siRNA Transfection and shRNA Retroviral
Transduction
For transient gene silencing, 25 nM of siRNA were transfected
using LipofectamineRNAiMax (Life Technologies). The following
silencing duplexes were used: predesigned MISSION siRNA
against human DHH (CUUGCUACGCGGUUCUGGA; Sigma,
St-Quentin-Fallavier, France), duplexes against human PTCH1
(HSS108758, Life Technologies) and human PTCH2 (HSS112667,
Life Technologies), and non-silencing control siRNA (sic, Life
Technologies). Preparation of sic and DHH siRNA-transfected
BTICs-conditioned media (BTICs-CM) was performed 2 days
post-transfection.
Stable knockdown of DHH was performed in retrovirally-
infected BTICs as described previously (Dubois et al., 2014).
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Briefly,HEK-293T cells were transfectedwith amixture of pVSVg,
pSPAX2, and pGIPZ-GFP or pGIPZ-GFP-DHH shRNA (Thermo
Fisher Scientific, Illkirch, France). Supernatants were collected
2 days post-transfection, clarified by centrifugation and used
to transduce BTICs. Transduction and knockdown efficiency
were checked by flow cytometry and RT-PCR, respectively, prior
implantation in animals.
Gene Array Analysis
Monolayers of quiescent hCMEC/D3 cells were exposed for 24 h
to four different patient-derived BTICs-derived condition media.
Endothelial RNAs were purified (Qiagen, Courtaboeuf, France)
and labeled (Ambion) for transcriptome (Affymetrix, eBioscience,
Hatfield, UK) and statistical analysis (Genom’IC core facility,
Institut Cochin, Paris, France).
Reverse Transcription-Polymerase Chain
Reaction
Purified RNA (Qiagen) were processed for reverse transcription
using the Maxima RT Kit (Thermo Fisher) and used to amplify
human PTCH2, PTCH1, DHH, DHRS3, ODZ2, EBF4, LPPR5,
RHOU,NXPH4, GAPDH, and BACT. RedTaq ReadyMix (Sigma)
and specific primer setswere used for PCR, as described in (Leclair
et al., 2014).
Flow Cytometry Analysis
Ptch1 and Ptch2 expression were analyzed using an indirect
immunofluorescence protocol. Cells were incubated with primary
antibodies (Ptch2 SAB2101905 and Ptch1 AV44249, Sigma),
washed three times with cold phosphate-buffered saline and
further stained with the corresponding Alexa488-conjugated
IgG (Life Technologies). Data were acquired on a FACScalibur
(CellQuest software; BD) and analyzed using FlowJo (Ashland,
OR, USA).
ELISA
Desert hedgehog (DHH) and Sonic hedgehog (SHH) secreted
concentrationswere analyzed byELISA assay as described in (Azzi
et al., 2010). Briefly, 50 ml of BTICs-CM were coated in a 96 well
ELISA plate at 4°C overnight, and saturated (BSA 3%, 30 min).
Primary antibodies (DHH SAB1407419 and SHH SAB2108581,
Sigma), were then added, washed five times with a PBS-Tween
0.5% solution, and further stained with the corresponding HRP-
conjugated IgG. Plates were washed five times, and 50 ml of TMB
substrate (Sigma) was added for 20 min in the dark. Absorbance
was read at 650 nm. Recombinant DHH (Emelca Bioscience) and
SHH (Sigma) were used to establish the standard curves.
Tubulogenesis Assay
Tubulogenesis assay was performed as previously described
(Dwyer et al., 2012). Briefly matrigel was added to a 96-well
plate and allowed to polymerize for 30 min at 37°C. hCMEC/D3
endothelial cells (10,000 cells/well) were pre-treated with BTICs-
CM for 24 h, prior being seeded on top of matrigel. Images
of at least five fields of view (FOV) per condition, randomly
chosen, were acquired each hour over an 8-h period (Motic, AE21
microscope,Wetzlar, Germany). For tube formation and branches
quantifications, images were processed using ImageJ software
(NIH, Bethesda, MD, USA).
Sprouting Assay
Sprouting of hCMEC/D3 cells was assessed as described in
(Wimmer et al., 2012). Briefly, 4000 Cytodex3 microcarrier beads
(Sigma) were coated with collagen (BD Biosciences), and mixed
with 106 hCMEC/D3 cells in warm EBM-2 medium. The mixture
was incubated for 4 h at 37°C, with regular shaking (each 15 min).
Coated beads were transferred to a new culture dish overnight
to remove unattached cells, then washed with PBS and re-
suspended in a 2.5 mg/ml fibrinogen-aprotinin (0.15 Units/ml,
Sigma) solution + bFGF2 (200 ng/ml, Sigma). The mixture was
then distributed in eight wells Ibidi plate containing 0.625 U/mL
of thrombin, and allowed to clot for 15 min at 37°C. EBM-2
medium or BTICs-CMwere added on top of the fibrinmatrix and
sprouting allowed for 3 days.
For imaging, matrix containing-beads were fixed (PFA 4%,
30 min), permeabilized (Triton 0.5%, 10 min), and saturated
(BSA 3%, overnight at 4°C). Phalloidin and DAPI labeling
were performed and images acquired using Leica fluorescence
microscope (Imagery facility, Institut Cochin, Paris). Number of
sprouting cells and sprout length, in at least five FOV randomly
chosen, were quantified using ImageJ software.
Permeability Assays
In vitro and in vivo permeability assays were conducted as
described in (Gavard and Gutkind, 2006; Le Guelte et al., 2012;
Treps et al., 2015). Briefly, for in vitro assay, 1.105 hCMEC/D3 cells
were seeded on 3mmpore-size collagen-coated PTFEmembranes
(Costar, VWR, Fontenay-sous-Bois, France) for 3 days. Cells
were then treated with BTICs-CM for 24 h, and permeability
evaluated by FITC-dextran 40 kDa passage. Fluorescence was
measured using the Fusion plate reader (Packard, San Diego,
CA, USA). Data were normalized to untreated samples and
expressed as the mean on three independent experiments. For
in vivo miles assay, sterile Evans blue (1% in PBS, Sigma) was
administrated by retro-orbital injection in ketamine/xylazine
mixture (50 and 5 mg/kg) anesthetized animals. Mice were
sacrificed 30 min later, and intra-tumor blue extravasation
evaluated by absorbance. Results were normalized to skin
punctures.
Xenografts and Tissue Staining
Brain tumor-initiating cells transduced with shRNA against
DHH or non-silencing shRNA control were re-suspended in
a mixture of PBS/matrigel (1:1), and injected subcutaneously
(1.106 cells/injection) in the flank of BALB/c nude mice. Tumor
formation and volume were assessed over the duration of
the experiment and quantified using following the equation:
volume = (width2  length)/2 formula, in a double-blind
study. To evaluate intra-tumor hypoxic zones, pimonidazole
was administrated at 30 mg/kg by intravenous injection,
1 h prior mice sacrifice and tumor extraction. Tumors were
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cryopreserved in OCT to be later processed for imaging
analysis.
Tissue sections were obtained using Leica cryostat (Histology
core-facility, Cochin Institute, Paris, France). Sections were fixed
(PFA 4% for 30 min), permeabilized (Triton 0.5%, 10 min),
saturated (BSA 3%, 2 h) and incubated with CD31 antibody
(1/200, overnight at 4°C, BD Biosciences). Tissue samples were
washed and further incubated with corresponding FITC-coupled
secondary antibody for 1 h. Alternatively, sections were incubated
with Hp-Dylight™549 conjugated antibody overnight at 4°C.
Images of five different FOV of three different sections were
acquired using Leica fluorescence microscope, and staining
quantified using the ImageJ software.
All statistical analyses were performed on two or three
independent experiments, using Prism software (GraphPad, La
Jolla, CA, USA).
RESULTS
Secretome of Patient-Derived
Glioblastoma-Initiating Cells Impacts
on Brain Endothelial Cell Plasticity
While previous studies had highlighted the importance of the
vascular niche in maintaining the BTICs population (Calabrese
et al., 2007; Galan-Moya et al., 2011), how in turn BTICs might
impact on endothelial fate is poorly documented. We thus
explore the effects of patient-derived BTICs-secreted factors on
endothelial cell remodeling. To this aim, confluent monolayers
of human endothelial brain endothelial cells (hCMEC/D3)
cells were exposed to BTICs-CM for 24 h. BTICs-CM induced
tubule formation and branching to the same extent as VEGF-A.
Interestingly, this effect was significantly higher than serum-
free EBM-2 medium (Ctl) and was recapitulated in all 14
patient-derived BTICs tested (Figure 1A). Accordingly, BTICs-
CM promoted hCMEC/D3 sprouting from collagen-coated
microcarriers (Figure 1B). Indeed, both sprout length and
sprout number were elevated, when compared to control
conditions, albeit slightly lower than VEGF-A-treated conditions
(Figure 1B). As VEGF-A is a key driver of endothelial plasticity
(Folkman, 2006; Gavard and Gutkind, 2006), we next assessed
whether it was required for BTICs-CM-triggered angiogenic
phenotype. While inhibiting VEGF-R2 tyrosine kinase activity
resulted in a dramatic reduction in both sprouting length and
number of sprouting cells upon VEGF-A stimulation, no overt
changes were observed when exposed to BTICs-CM (Figure 1C).
Furthermore, BTICs-CM heightened endothelial permeability,
as indicated by a two-fold increase of FITC-dextran passage
(Figure 1D), an effect seen in all the 14 GBM patient-derived
BTICs tested. Again, it is unlikely this effect is dependent on
VEGF-A, as blocking Src kinase activity; the main downstream
regulator of VEGF-A-induced permeability (Eliceiri et al.,
1999; Gavard and Gutkind, 2006); only partially reduced
the BTICs-CM-triggered endothelial permeability increase
(Figure 1E). Thus, our data suggest that BTICs-released factors
induce endothelial cell remodeling in a VEGF-independent
manner.
Ptch2 Receptor is Upregulated
in BTIC-CM-Exposed Endothelial Cells
In order to gain further insights into the molecular mechanisms
involved in BTICs-based action, a transcriptome analysis of
endothelial cells exposed to four different BTICs-CM (#1, #2,
#3, #4) was performed, and a heat map of up- and down-
regulated genes was generated (Figure 2A). Statistical analysis
of shared genes with modified expression of at least two fold,
and a p value of <0.05 was performed revealing seven genes
of interest. PTCH2, DHRS3, ODZ2, EBF4, LPPR5, RHOU, and
NXPH4 were found in silico to be significantly up-regulated
in treated cells, when compared to untreated endothelial cells.
An independent RNA analysis confirmed the up-regulation of:
PTCH2, ODZ2, and LPPR5 (Figure 2B). Among these three
candidates, we next focused on PTCH2, one of the two HH
receptors. Indeed, HH signaling is aberrantly activated in many
cancers and contributes to both tumor (Smyth et al., 1999)
and blood–brain barrier development (Alvarez et al., 2011).
Moreover, HH signaling was reported to supervise tumor-
initiating cell fate and phenotype (Bar et al., 2007; Justilien
et al., 2014; Takebe et al., 2015). In this context, PTCH2
expression was observed in three different endothelial cell
lines, only upon BTICs-CM challenge (Figure 2C), suggesting
that this effect was not restricted to brain microcirculation.
Further flow cytometry analysis showed that at various levels,
Ptch2 was upregulated in response to a large panel of BTICs-
CM (Figures 2D,E), suggesting that Ptch2 up-regulation is not
a BTICs-type dependent phenomenon. Interestingly, PTCH1
expression remained unchanged in control and treated cells
(Figures 2C,D). To address the functional role of Ptch2 in
endothelial cells, RNA interference was employed to prevent
BTICs-CM-driven up-regulation (Figures 2F–G). When Ptch2
was no longer induced, endothelial permeability and sprouting
were significantly impaired (Figures 2H,I). Interestingly, Ptch1
siRNA failed to phenocopy Ptch2 silencing (Figures 2H,I).
Finally, endothelial responses to VEGF-A were left intact in terms
of sprouting and permeability (Figures 2H,I), reinforcing the
VEGF-independent property of BTICs-secreted factors.
Desert Hedgehog Mediates Permeability
and Angiogenesis in Brain Endothelial Cells
We next investigated which of the three known ligands of
Ptch2 could be released in BTICs-CM or in endothelial cell-
CM. DHH was notably detected in the 14 different BTICs-CM
at the average concentration of 15 ng/ml, while sonic hedgehog
(SHH) could not be detected (Figure 3A). Because endothelial
cells do not secrete any of these ligands, unlike U87 glioma
cells, an autocrine action of HH ligands on brain endothelial
cells was discarded (Figure 3A). Thus, we further investigated
how BTICs-secretedDHH couldmodify endothelial homeostasis.
Upon DHH silencing, BTICs-mediated Ptch2 upregulation was
quelled, suggesting that Ptch2 could be its own direct target
in a positive feedback loop, as demonstrated previously in HH
signaling (Figures 3B,C,D; Evangelista et al., 2006; Aberger et al.,
2012). Interestingly, BTICs-CM no longer induced permeability
(Figure 3E), and depletion of DHH dramatically reduced the
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FIGURE 1 | Patient-derived BTICs-secreted factors induced brain endothelial cell remodeling, independently of the VEGF-R2/Src axis. (A) Brain
endothelial hCMEC/D3 cells were tested for tube formation capacity in response to VEGF and all 14 BTICs-derived conditioned media. Representative images are
shown. Tube length and number of branch points per field of view (FOV) were quantified. (B,C) hCMEC/D3 cells sprouting ability was evaluated in the absence (B) or
presence (C) of the VEGF R2 inhibitor SU5416 (5 mM). The number of sprouting cells and mean sprout length were determined. (D,E) Permeability of brain
endothelial cells treated with BTICs-derived conditioned media. Cells were pre-treated with DMSO (Vehicle) or SU6656 (Src inhibitor, 1 mM) prior BTICs-CM
treatments in (E). Data are expressed as fold change relative to the control. ***p < 0.001, **p < 0.01, *p < 0.05 by analysis of variance (ANOVA). Each panel is
representative of at least three independent experiments.
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FIGURE 2 | The Hedgehog receptor Ptch2 is up-regulated in BTIC-CM-exposed brain endothelial cells. (A) Gene array analysis of hCMEC/D3 cells
exposed to BTIC-derived conditioned media for 24 h. Untreated endothelial cells were used as control. (B) Gene array confirmation by RT-PCR of seven up-regulated
genes common to all treated conditions. Actin (ACTB) was used as a reference gene. (C) RT-PCR analysis of PTCH2 expression in three different types of endothelial
cells. Confluent monolayers of hCMEC/D3, hBMEC, and HUVEC cells were exposed to BTIC-derived conditioned media for 24 h, and PTCH2 expression analyzed
by RT-PCR. Actin (ACTB) was used as a reference gene. (D,E) hCMEC/D3 cells were analyzed by flow cytometry for total Ptch1 and Ptch2 expression before (Ctl)
and after BTICs-derived conditioned media stimulation (BTIC-CM, 24 h). In (D), dashed histograms correspond to the isotype-matched control (Ig) and gray and
black histograms show antibody staining of control and stimulated conditions, respectively. Mean of fluorescence of 10,000 events (MFI) for Ptch2 expression in
untreated (Ctl) versus stimulated (BTIC-CM) endothelial cells is shown in (E). (F–H) hCMEC/D3 cells were transfected with control (sic) or siRNA against Ptch1
(siPtch1) or Ptch2 (siPtch2). For Ptch2 silencing, 48 h after receiving the siRNA, endothelial cells were further stimulated with BTIC-CM for another 24 h in order to
induce Ptch2 expression. (F) Ptch1 and Ptch2 expression were analyzed by RT-PCR. Actin (ACTB) was used as a reference gene. (G) Ptch1 and Ptch2 expression
were analyzed by flow cytometry. Dashed histograms correspond to the isotype-matched control (Ig) and gray and black histograms show antibody staining in
endothelial cells treated as indicated. (H) Permeability of endothelial cells was assessed. (I) hCMEC/D3 cells were also tested for their sprouting capacity. The number
of sprouting cells and mean sprout length were determined. ***p < 0.001, **p < 0.01 by analysis of variance (ANOVA). Each panel is representative of at least two
independent experiments.
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FIGURE 3 | DHH mediates the BTICs-CM effects in brain endothelial cells. (A) SHH and DHH secretion was examined by ELISA in BTICs and endothelial cells
(EC) conditioned media. U87 were used as a positive control. (B) BTICs cells were transfected with either control (sic) or siRNA against DHH (siDHH). Conditioned
media was collected and processed for DHH secretion by ELISA assay. Alternatively, mRNA were extracted from both sic and siDHH receiving cells, and DHH
expression was assessed by RT-PCR. GAPDH was used as a reference gene. (C–G) Confluent monolayers of hCMEC/D3 cells were exposed for 24 h to
BTICs-conditioned media depleted (siDHH) or not (sic) for DHH. Ptch2 expression was assessed by RT-PCR (C) and flow cytometry analysis (D). Dashed histograms
correspond to the isotype-matched control (Ig), black and blue histograms show antibody staining in endothelial cells treated as indicated. (E) Permeability of
endothelial cells was analyzed. (F,G) Endothelial cells were also tested for their sprouting (F) and tube formation (G) ability. The number of sprouting cells and mean
sprout length were determined in (F). Tube length, and number of branch points were counted in (G). ***p< 0.001, **p< 0.01 by analysis of variance (ANOVA). Each
panel is representative of at least two independent experiments.
BTICs-CM pro-angiogenic effects, as assessed by sprouting and
tubulogenesis ability (Figures 3F,G). Taken together, these results
indicate that BTICs induce the expression of Ptch2 receptor in
endothelial cells, while producing DHH ligand in the medium,
thus enabling a paracrine DHH/Ptch2 signaling cascade that
culminates in endothelial remodeling.
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FIGURE 4 | DHH drives vascular dysfunctions in vivo. (A–C) BTIC#9 cells received either control (sic) or siRNA against DHH (siDHH). (A) Cells were processed
for DHH expression by RT-PCR. ACTB was used as a reference gene. (B) BTICs cells were tested for their neurospheres formation capacity. Representative images
are shown. The number of spheres per field of view (FOV) was quantified. (C) Cell viability was analyzed using trypan blue staining. (D–H) BTICs cells were stably
transfected with control (shC) or two shRNAs against DHH (sh2 and sh4) plasmids. (D) DHH expression and secretion was analyzed by RT-PCR and ELISA. (E)
BTICs cells were injected subcutaneously in each flank of nude mice, and tumor-baring mice counted 12 weeks later. (F) Tumor volume was evaluated. (G) Frozen
tissue sections from obtained tumor xenografts were stained with CD31 and Hpi. Staining intensity was quantified using Image J. (H) Intra-tumor vascular
permeability was measured using in vivo Miles assay. ***p < 0.001, **p < 0.01, *p < 0.05 by analysis of variance (ANOVA).
Desert Hedgehog Drives Vascular
Dysfunctions in Mice
Finally, we explored the contribution of the paracrine
DHH/Ptch2 signaling in vivo, using ectopic subcutaneous
xenografts. Importantly, DHH silencing did not influence BTICs
tumorspheres formation and viability (Figures 4A–C). Indeed,
DHH-silenced BTICs maintained their self-renewal ability, as
evidenced by the tumorspheres formation (Figure 4B), while
their viability rate remained similar to control cells (Figure 4C).
BTICs stably depleted for DHH expression were engineered
and two clones (sh2 and sh4) were selected for their silencing
efficiency and compared to cells that receive a non-silencing
shRNA (shC). Accordingly, DHH expression and secretion were
dramatically reduced in both sh2 and sh4 clones (Figure 4D).
The reduction of DHH production had no significant effect
on tumor initiation in vivo, as the number of tumor-bearing
mice scored higher than 2/3 in each group within 12 weeks
(Figure 4E). However, DHH loss-of-function in BTICs had a
dramatic effect on tumor growth, as sh2 and sh4 clones produced
tumors four times smaller than controls (Figure 4F). Likewise,
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vessels (CD31 staining) and hypoxic zones (Hpi staining) density
were alleviated in DHH-less xenografts (Figure 4G). Accordingly,
this effect was associated with a restrained intra-tumor vascular
leakage (Figure 4H). Collectively, these results unveil a role
for DHH in exacerbated tumor angiogenesis and permeability,
which can ultimately favor glioblastoma growth, and thus place
the DHH/Ptch2 nexus as a potential candidate for therapeutic
intervention.
DISCUSSION
In summary, we report here that glioblastoma-initiating cells,
which compose a small fraction of cells able to self-renew and
drive tumorigenesis, promote brain endothelial cell remodeling
though aberrant HH signaling. Indeed, we found that BTICs
released DHH ligand in the extracellular space, while inducing
Ptch2 expression in endothelial cells. Additionally, DHH ligand
elicits a signaling cascade, through its receptor Ptch2, ultimately
impacting on endothelial plasticity.
The HH family is composed of three members, Sonic (SHH),
Desert (DHH), and Indian (IHH) that serve as ligands for PTCH
receptors, Ptch1 and Ptch2 (Echelard et al., 1993; Riddle et al.,
1993). Of note, the HH pathway is aberrantly activated in many
cancers, and contributes both to tumor progression in various
organs such as brain, lung, and skin (Vorechovsky et al., 1997;
Evangelista et al., 2006) and to control the fate of tumor-initiating
cells (Bar et al., 2007; Justilien et al., 2014; Takebe et al., 2015).
Indeed, HH plays an essential role in driving tumorigenesis and
drug resistance (Filbin et al., 2013), along with favoring cancer-
initiating phenotype (Bar et al., 2007). HH can also enhance
the expression of angiogenic factors, such as angiopoietins (Lee
et al., 2007). Interestingly, we found that DHH does not seem
to be involved in maintaining BTICs. Indeed, DHH silencing
did not influence BTICs tumorspheres formation and viability.
Conversely, DHH largely contribute to BTICs-CM impact on
brain endothelial cell behavior in vitro and tumor angiogenesis in
vivo. In keeping with this idea, it has been reported that HH nexus
is instrumental in maintaining the blood–brain barrier integrity
during both development and adulthood in mouse models
(Alvarez et al., 2011). In this context, pharmacological inhibitors
targeting Src kinase activity did not fully abrogate BTICs-CM-
triggered endothelial behavior. Indeed, the partial blockade of
endothelial permeability increase obtained by Src inhibitionmight
be attributed to the presence of other pro-permeability factors
in the BTICs-CM, among which are Semaphorin 3A and VEGF-
A (Bian et al., 2007; Dwyer et al., 2012; Le Guelte et al., 2012;
Treps et al., 2015). Meanwhile, hindering VEGF-R2 tyrosine
kinase activity did alter BTICs-CM action on brain endothelial
cells. Overall, these observations suggest that DHHmight operate
independently of VEGF-A in the tumormicroenvironment. Thus,
DHHmight emerge as a novel pro-permeability factor and a novel
candidate for anti-edema and anti-angiogenic therapeutic actions.
Whereas Ptch1 signaling is widely documented, Ptch2 modus
operandi and functions continue to be elucidated. For instance,
Ptch1 triggers both a canonical and non-canonical signaling
pathways (Aberger et al., 2012), and can synergize with PI3K
pathway to promote tumor growth and viability in GBM.
Accordingly, blockade of both pathways simultaneously resulted
in mitotic catastrophe and tumor apoptosis (Filbin et al., 2013).
Here, we found that Ptch1 expression in endothelial cells
was not affected by BTIC-CM challenge. Likewise, silencing
Ptch1 fails to stop BTIC-mediated endothelial remodeling.
Furthermore, SHH was not secreted by either BTICs or
endothelial cells, suggesting that the canonical SHH/Ptch1
pathway does not function in the co-culture system. Interestingly,
it has been recently documented that Ptch2 could suppress
SHH signaling (Alfaro et al., 2014). In this scenario, Ptch2
expression in endothelial cells might counteract the effects
of SHH locally secreted by other cell types from the tumor
mass, such as astrocytes and stromal cells. Collectively, our
data suggest that Ptch2 upregulation in endothelial cells and
further ligand activation cause an imbalanced HH signaling, that
can account for the observed vascular dysfunctions and barrier
disruption, while sparing SHH positive impact on tumor cell
expansion.
Our results demonstrate that targeting the DHH/Ptch2 nexus
emerges as an appealing approach to curb vascular dysfunctions
in GBM. Indeed, ablation of HH signaling may interfere
with both angiogenesis and vascular leakage, and thus tumor
growth. Nevertheless, further studies addressing the receptor
upregulation mechanism and its elicited signaling route are
required. Overall, our work unveils a role for DHH in heightened
tumor angiogenesis and permeability, which may ultimately favor
GBM progression, and thus places the DHH/Ptch2 nexus as a
putative target for novel therapies directed against malignant
stem-cell niches in GBM.
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